Rcombinant botulinum neurotoxin type A for injection (YY001)
Sponsors
Chongqing Claruvis Pharmaceutical Co., Ltd.
Conditions
Moderate to Severe Glabellar Lines
Phase 3
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
CompletedNCT06499688
Start: 2023-12-28End: 2024-05-31Updated: 2024-07-24
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
CompletedNCT06583486
Start: 2024-03-19End: 2025-08-25Updated: 2026-06-29